Prophase Labs (PRPH) 2025 ThinkEquity Conference summary

Key assets and business initiatives

• Three main assets: Crown Medical collections, BE-Smart esophageal cancer test, and Nebula Genomics.

• Crown Medical is pursuing $150M in unpaid COVID testing claims, expecting to net $50M in cash via contingency litigation.

• BE-Smart esophageal cancer test recently published in a major journal, enabling commercialization efforts.

• Nebula Genomics offers whole genome sequencing and holds a large, valuable genetic database.

• ProPhase supplements include Equivir, a broad-based antiviral with commercialization potential.

Financial and operational turnaround

• Company previously generated $300M in COVID testing revenue but only collected $150M, leading to cash constraints.

• Overhead increased due to expectations of government reimbursement, but funding ceased, resulting in debt.

• Management restructured, overhead reduced, and business cleaned up to operate at break-even.

• Anticipated cash inflow from Crown Medical expected to transform financial position within months.

• Previous successful turnarounds and asset sales cited as evidence of management capability.

Legal and collection strategy

• Crown Medical, with dozens of attorneys, is pursuing underpaid insurance claims for 40 labs, including this one.

• Bankruptcy court strategy enables efficient litigation against 1,100 insurance companies.

• Insurance companies are incentivized to settle due to risk of exposure and multi-state claims.

• Settlements expected to begin in coming months, with $50M net cash anticipated.

• Appointment of Crown Medical as special counsel is imminent, expediting litigation.